Drug manufacturer Sanofi yesterday sent the U.S. Health Resources and Services Administration (HRSA) a 30-page defense of its requirement that 340B covered entities must submit their contract pharmacy claims data to a vendor to continue to be able to access 340B pricing on Sanofi products.
Sanofi was responding to HRSA’s May 17 letter informing the company that its policy violated the 340B statute and had to be revoked immediately. HRSA sent five other manufacturers that have stopped or restricted 340B contract pharmacy usage similar demand letters. It asked the companies to describe by June 1 how they plan to resume selling their products without restriction to covered entities that use contract pharmacies. HRSA said non-compliance could be punishable with civil monetary penalties of up to $5,883.00 for each instance of overcharging.
Drug manufacturer Sanofi yesterday sent the U.S. Health Resources and Services Administration (HRSA) a 30-page defense of its requirement that 340B covered entities must submit their contract pharmacy claims data to a vendor to continue to be able to access 340B pricing on Sanofi products.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
